secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quanterix Corp (QTRX)
CIK:        0001503274
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001503274-26-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quanterix Q1 revenue $36.4M (+20% YoY); reaffirms FY2026 guidance of $169-174M
------------------------------------------------------------------------------

- Revenue of $36.4M, up 20% YoY; GAAP gross margin 42.7%, adjusted 50.9%.
- Adjusted EBITDA loss $9.8M, improved from $11.3M loss a year ago.
- Cash and marketable securities $102.6M; targeting cash flow breakeven in H2 2026.
- Alzheimer's diagnostics business growing; 510(k) filing with FDA expected in H2 2026.
- Collaborations with Tempus AI and Life Line Screening for blood-based biomarker tests.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1503274/000150327426000019/0001503274-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1503274/000150327426000019/qtrx-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001503274-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer